A humanized monovalent CD3 antibody which can activate homologous complement.
The rat monoclonal antibody (mAb) YTH12.5, specific for the CD3 antigen complex on human T cells has been modified in order to improve its efficacy in human therapy. With the aim of rendering it less immunogenic, it has been humanized using the method of framework grafting. During this process seque...
Main Authors: | Routledge, E, Lloyd, I, Gorman, S, Clark, M, Waldmann, H |
---|---|
Format: | Journal article |
Language: | English |
Published: |
1991
|
Similar Items
-
The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties.
by: Bolt, S, et al.
Published: (1993) -
The improved lytic function and in vivo efficacy of monovalent monoclonal CD3 antibodies.
by: Clark, M, et al.
Published: (1989) -
COMPLEMENT LYSIS MEDIATED BY ENGINEERED MULTIPLE-DOMAIN FORMS OF THE THERAPEUTIC ANTIBODY CAMPATH-1H
by: Greenwood, J, et al.
Published: (1994) -
Engineering multiple-domain forms of the therapeutic antibody CAMPATH-1H: effects on complement lysis.
by: Greenwood, J, et al.
Published: (1994) -
Reshaping a therapeutic CD4 antibody.
by: Gorman, S, et al.
Published: (1991)